• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    21 Stocks Moving in Friday's Pre-Market Session

    6/17/22 5:51:14 AM ET
    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Athersys, Inc. (NASDAQ:ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) rose 31.2% to $0.3701 in pre-market trading after jumping 100% on Thursday.
    • Blackboxstocks Inc (NASDAQ:BLBX) rose 27.7% to $1.66 in pre-market trading. Blackboxstocks reports in Form4 Filing that Director Ray Balestri bought 71,366 shares at an average price of $1.22 per share.
    • Revlon, Inc. (NYSE:REV) rose 20% to $2.34 in pre-market trading after the company filed for Chapter 11 bankruptcy.
    • ObsEva SA (NASDAQ:OBSV) shares rose 13.1% to $2.07 in pre-market trading after the company said the European Commission granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the treatment of uterine fibroids.
    • Exela Technologies, Inc. (NASDAQ:XELA) rose 12.3% to $0.16 in pre-market trading. Exela Technologies recently named Lakshmi Narayanan Chandramohan to President, Bills and Payments.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) rose 11.2% to $3.47 in pre-market trading.
    • Akanda Corp. (NASDAQ:AKAN) rose 8.9% to $1.34 in pre-market trading after jumping over 32% on Thursday.
    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 8.8% to $17.32 in pre-market trading.
    • Ballard Power Systems Inc. (NASDAQ:BLDP) shares rose 8.4% to $6.33 in pre-market trading after declining more than 6% on Thursday.
    • BARK, Inc. (NYSE:BARK) shares rose 6.7% to $1.43 in pre-market trading after declining 8% on Thursday.
    • Arrival (NASDAQ:ARVL) rose 6.1% to $1.39 in pre-market trading after dropping 9% on Thursday.

    Don’t forget to check out our premarket coverage here .

    Losers

    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares fell 34.8% to $2.18 in pre-market trading as the company said it has terminated dipraglurant Phase 2b/3 study in patients with dyskinesia associated with Parkinson’s Disease due to slow recruitment rate.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 24.5% to $2.30 in pre-market trading after dipping 15% on Thursday.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) fell 12.5% to $3.41 in pre-market trading. The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 11% to $0.5503 in pre-market trading. Acorda Therapeutics shares jumped around 55% on Thursday after the company announced Esteve Pharmaceuticals GmbH launched INBRIJA in Germany.
    • Tantech Holdings Ltd (NASDAQ:TANH) shares fell 10.5% to $0.2416 in pre-market trading.
    • Aeterna Zentaris Inc. (NASDAQ:AEZS) shares fell 8% to $0.1610 in pre-market trading. Aeterna Zentaris recently achieved proof-of-concept for the treatment of NMOSD with AIM biologicals program.
    • SeaChange International, Inc. (NASDAQ:SEAC) fell 7.4% to $0.5648 in pre-market trading. SeaChange and Triller, recently announced they mutually agreed to terminate their proposed merger.
    • Vivakor, Inc. (NASDAQ:VIVK) fell 7.1% to $2.31 in pre-market trading. Vivakor shares jumped 40% on Thursday after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.
    • Aqua Metals, Inc. (NASDAQ:AQMS) shares fell 5.6% to $1.01 in pre-market trading after jumping 16% on Thursday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADXN
    $AEZS
    $AKAN

    CompanyDatePrice TargetRatingAnalyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Ballard Power Systems Inc.
    $BLDP
    1/9/2026Buy → Hold
    TD Cowen
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/5/2025Outperform → Perform
    Oppenheimer
    Ballard Power Systems Inc.
    $BLDP
    8/11/2025Buy → Hold
    Lake Street
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/10/2025$97.00Buy
    Goldman
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/7/2025$88.00Outperform
    Leerink Partners
    More analyst ratings

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 18, 2022 - FDA Alerts the Public to Potentially Contaminated Products from Family Dollar Stores in Six States

    For Immediate Release: February 18, 2022 Today, the U.S. Food and Drug Administration is alerting the public that several categories of FDA-regulated products purchased from Jan. 1, 2021, through the present from Family Dollar stores in Alabama, Arkansas, Louisiana, Mississippi, Missouri and Tennessee may be unsafe for consumers to use. The impacted products originated from the company’s distribution facility in

    2/18/22 8:06:10 PM ET
    $ARVL
    Auto Manufacturing
    Consumer Discretionary

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ballard Power downgraded by TD Cowen

    TD Cowen downgraded Ballard Power from Buy to Hold

    1/9/26 8:48:15 AM ET
    $BLDP
    Industrial Machinery/Components
    Energy

    Citigroup initiated coverage on Rhythm Pharmaceuticals with a new price target

    Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00

    11/25/25 8:45:08 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by West Eric

    4 - Aqua Metals, Inc. (0001621832) (Issuer)

    4/15/26 4:22:25 PM ET
    $AQMS
    Metal Fabrications
    Industrials

    SEC Form 4 filed by Taecker Benjamin S.

    4 - Aqua Metals, Inc. (0001621832) (Issuer)

    4/15/26 4:22:01 PM ET
    $AQMS
    Metal Fabrications
    Industrials

    SEC Form 4 filed by Cotton Stephen

    4 - Aqua Metals, Inc. (0001621832) (Issuer)

    4/15/26 4:21:35 PM ET
    $AQMS
    Metal Fabrications
    Industrials

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

    Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, a

    4/23/26 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. "These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM," said Tim Dyer, CEO of Addex. "Chronic cough is a

    4/21/26 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ballard welcomes Ralph Robinett as Chief Operating Officer

    VANCOUVER, BC, April 13, 2026 /CNW/ - Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) today welcomed Ralph Robinett as Senior Vice President and Chief Operating Officer, replacing Lee Sweetland, effective April 13th, 2026. Ralph brings more than 25 years of global operations, manufacturing, supply chain, and transformation leadership experience across advanced technology and clean energy businesses. He has led large-scale operational organizations, built and expanded manufacturing facilities in multiple regions, driven cost reduction and productivity improvement initiatives, and

    4/13/26 7:30:00 AM ET
    $BLDP
    Industrial Machinery/Components
    Energy

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Ibrahim Zahir bought $50,523 worth of shares (58,823 units at $0.86) (SEC Form 4)

    4 - Bark, Inc. (0001819574) (Issuer)

    6/16/25 4:27:36 PM ET
    $BARK
    Other Specialty Stores
    Consumer Discretionary

    Chief Financial Officer Ibrahim Zahir bought $128,748 worth of shares (105,555 units at $1.22) (SEC Form 4)

    4 - Bark, Inc. (0001819574) (Issuer)

    6/11/25 7:23:41 PM ET
    $BARK
    Other Specialty Stores
    Consumer Discretionary

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    SEC Filings

    View All

    SEC Form 6-K filed by Ballard Power Systems Inc.

    6-K - Ballard Power Systems Inc. (0001453015) (Filer)

    4/24/26 9:55:40 AM ET
    $BLDP
    Industrial Machinery/Components
    Energy

    SEC Form 6-K filed by Addex Therapeutics Ltd

    6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

    4/23/26 6:05:05 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Addex Therapeutics Ltd

    6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

    4/21/26 6:05:05 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Leadership Updates

    Live Leadership Updates

    View All

    Ballard welcomes Ralph Robinett as Chief Operating Officer

    VANCOUVER, BC, April 13, 2026 /CNW/ - Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) today welcomed Ralph Robinett as Senior Vice President and Chief Operating Officer, replacing Lee Sweetland, effective April 13th, 2026. Ralph brings more than 25 years of global operations, manufacturing, supply chain, and transformation leadership experience across advanced technology and clean energy businesses. He has led large-scale operational organizations, built and expanded manufacturing facilities in multiple regions, driven cost reduction and productivity improvement initiatives, and

    4/13/26 7:30:00 AM ET
    $BLDP
    Industrial Machinery/Components
    Energy

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rhythm Pharmaceuticals Announces Changes to Board of Directors

    -- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. "We are thrilled to welcome Kim to our Board of Directors," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record

    4/3/26 9:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

    BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update. Also today, Rhythm announced that Hunter Smith, Chief Financial Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:00 a.m. ET. Live webcasts of both the financial results conference call and the

    4/9/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ballard Announces Q1 2026 Results Conference Call

    VANCOUVER, BC, April 7, 2026 /CNW/ - Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) will hold a conference call on Tuesday, May 5th, 2026 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to review first quarter 2026 operating results. The live call can be accessed by dialing +1-833-821-2814 (Canada/US toll free). Alternatively, a live webcast can be accessed through a link on Ballard's homepage (www.ballard.com), in the 'Latest News' section. Following the call, a link to the webcast will be available in the 'Investor Hub' area of the 'Investors' section of Ballard's website

    4/7/26 7:30:00 PM ET
    $BLDP
    Industrial Machinery/Components
    Energy

    Aqua Metals Reports 2025 Milestone Advancements, Strategic Progress, and Continued Commercialization Momentum

    RENO, Nev., March 31, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ:AQMS) ("Aqua Metals" or "the Company"), a pioneer in sustainable battery metals recycling and refining, today announced key achievements from 2025 and outlined continued momentum as the Company advanced commercialization of its proprietary AquaRefining™ technology, expanded its product platform, strengthened its financial position, and broadened its strategic role in the domestic critical minerals supply chain. During 2025, Aqua Metals made measurable progress through technology development, commercial readiness, product validation, strategic partnerships, and capital formation. The Company refined its commercializat

    3/31/26 4:05:00 PM ET
    $AQMS
    Metal Fabrications
    Industrials

    $ACOR
    $ADXN
    $AEZS
    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Exela Technologies Inc.

    SC 13D/A - Exela Technologies, Inc. (0001620179) (Subject)

    12/3/24 4:01:40 PM ET
    $XELA
    Business Services
    Consumer Discretionary

    SEC Form SC 13D filed by Exela Technologies Inc.

    SC 13D - Exela Technologies, Inc. (0001620179) (Subject)

    11/27/24 5:57:16 PM ET
    $XELA
    Business Services
    Consumer Discretionary

    SEC Form SC 13D filed by Exela Technologies Inc.

    SC 13D - Exela Technologies, Inc. (0001620179) (Subject)

    11/27/24 4:00:55 PM ET
    $XELA
    Business Services
    Consumer Discretionary